Can Hybrid Immunoassay and LC-MS Platforms Solve Key Challenges in Biologics Pharmacokinetics?
Assessing the pharmacokinetics (PK) of biologics involves navigating a range of analytical challenges—from ensuring assay sensitivity and managing critical reagents to meeting regulatory standards and scaling throughput. This insight brief explores how a hybrid bioanalytical platform that combines immunoassays with liquid chromatography–mass spectrometry (LC-MS) can overcome these hurdles. Learn how this integrated approach enhances accuracy, efficiency, and compliance in biologics PK analysis. We also examine the future of quantitative bioanalysis and the innovative technologies shaping the next generation of biologic drug development.
Complete the form below to access this insight brief
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
